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CHAPTER 1 
INTRODUCTION 
 
1.1. Enterococci species 
Enterococcus species are Gram-positive bacteria, which have gained 
importance as human pathogens for their distinctive property of being resistant to 
multiple antimicrobial agents (1). These species have similar physical 
characteristics to Streptococci and so are difficult to distinguish (2). Enterococci 
are responsible for a variety of infections including infective endocarditis, urinary 
tract infections, prostatitis, intra-abdominal infections, wound infections, cellulitis 
and concurrent bacteremia (1).  
Risk factors for enterococcal infections include prolonged hospitalizations, 
patients with compromised immune systems, patients who have undergone 
genitourinary surgical procedures or are admitted to the intensive care or the 
surgical units, patients who have been fitted with external medical devices like 
central intravenous catheter or urinary catheter and patients who have been 
administered multiple antibiotics (3). Enterococci are sturdy organisms and can 
survive in the hospital environment on various surfaces such as equipment used 
for medical procedures, toilets, door handles and beds and can survive heat and 
even alcohol preparations. 
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 Over 17 species of Enterococcus from human origin have been described, out 
of which more than 90% are Enterococcus faecium and Enterococcus faecalis 
(4). In the last decade, Enterococci have evolved as one of the leading causes of 
multiple antibiotic resistant nosocomial infections (5). High level of multi-drug 
resistance is one of the defining features of Enterococcus species. They are 
known to show characteristic intrinsic and acquired resistance to multiple 
antibiotics making them perilous nosocomial pathogens. The majority of the 
cases documented demonstrate resistance to β-lactam antibiotics (penicillins, 
cephalosporins, carbapenems) as well as aminoglycosides (6). Intrinsic 
resistance to several major classes of antibiotics either by acquisition of foreign 
genetic material or through mutation, are major contributors to these organisms 
being defined as serious nosocomial pathogens (6). Besides being intrinsically 
resistant to the β-lactam class of antibiotics, Enterococci have also acquired 
resistance to chloramphenicol, tetracyclines, rifampin as well as vancomycin 
which has been considered the last line antibiotic defense (7). Enterococcal 
resistance to β-lactams is driven by mutations that lead to altered penicillin-
binding protein (PBP) profiles which play a key role in the cross-linking of 
bacterial cell wall (8). These modified PBPs are able to carry out peptidoglycan 
synthesis while bypassing most beta-lactam agents (9). Before we discuss about 
resistance and how it works, knowledge about the treatment for such infections is 
important. 
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1.2. Treatment 
For treating Enterococcus infections, opting for the right drug or 
combination of drugs while keeping in mind the toxic side effects is very 
important. β-lactams are the most widely used antimicrobial agents to treat 
Enterococcal infections (10). They are indicated as the first-line treatment for 
such infections. Penicillin, ampicillin to be specific, is usually the drug of choice to 
combat Enterococcus infection. If the patient is allergic to penicillin or high-
resistance is observed then vancomycin is the drug that is preferred. 
Unfortunately, virulent strains of Enterococcus that are resistant to vancomycin 
have been reported (7). Therefore, therapeutic alternatives to vancomycin are 
needed which would combat such infections. One such therapy suggested in the 
literature is the therapy using daptomycin. Daptomycin non-susceptible strains 
have also been reported and to treat such strains, opting for multi-drug 
combination would be optimum (11). 
 
1.2.1. β-lactams and their mechanism of action 
β-lactam antibiotics such as penicillins often fail to show bactericidal 
activity against vancomycin-resistant enterococci (VRE) species. In some strains, 
resistance to penicillins can be developed by intermittent exposure to the 
antibiotics (12). 
β-lactam antibiotics act by inhibiting the synthesis of peptidoglycan layer, 
which is important for cell wall integrity. Peptidoglycan layer is the outermost 
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layer of bacterial cell wall. Penicillin-binding proteins (PBP) are responsible for 
synthesis of peptidoglycan layer. β-lactam antibiotics inhibit the action of PBPs 
and thus peptidoglycan layer is not formed. This leads to prevention of cross-
linking of the peptidoglycan layer resulting in a weak cell wall. 
As show in figure (1), blue colored band are N-acetylmuramic acid bands 
(NAM) and yellow colored bands are N-acetylglucosamine bands (NAG). 
Bacterial cell wall is made up of repeating NAM and NAG subunits. Short peptide 
chains are connected to the NAM subunits. These short peptide chains are made 
up of different compositions but it usually has L-Ala at the proximal end and two 
D-Ala on the distal end. Penicillin-binding proteins bind to these peptide chains, 
form a cross-link, and expel one molecule of D-Ala as shown in the step (B). 
Once the cross-link is formed as shown in step (C), PBPs disengage themselves 
from the peptide chains. This results in a healthy cell wall. In step (D) a β-lactam 
antibiotic is introduced; it enters the active site of PBP and irreversibly binds to 
the PBP making it ineffective as shown in step (E). This process disrupts the 
bacterial cell wall synthesis (8). 
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Figure (1) Mechanism of action of β-lactam antibiotics, (A.) cell wall before 
cross-linking, (B.) expulsion of a D-Ala molecules, (C.) cross-linking of cell wall, 
(D.) β-lactam antibiotic attacking the PBP, (E.) irreversible-binding of β-lactam 
antibiotic to the PBP 
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1.2.2. Daptomycin (DAP) and its mechanism of action 
 Daptomycin is a lipopeptide drug that shows extensive bactericidal activity 
against Gram-positive bacteria (13). The FDA approved dosage for DAP is 4-
6mg/kg, however documented clinical and in vitro results, show better results at 
higher doses (14-17). Daptomycin non-susceptibility breakpoint for 
Enterococcus species is 4 mg/L according to CLSI (Clinical & Laboratory 
Standard Institute) guidelines and any isolate with MIC >4mg/L is termed as 
DAP non-susceptible (DNS). 
 Daptomycin’s mechanism of action is calcium dependent. When DAP 
molecules comes in contact with the calcium in the blood they become positively 
charged. As shown in figure (2), DAP inserts its lipophilic tail into the bacterial 
cell membrane (18). This causes efflux of potassium ions causing the ion-
concentration gradient to be destroyed (19). This process leads to rapid 
depolarization of the membrane. Rapid depolarization results in failure of bio-
systems like DNA synthesis, RNA synthesis and protein synthesis, causing cell 
death (20). 
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Figure (2) Mechanism of action of Daptomycin 
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1.3. Mechanism of drug resistance in Enterococcus species 
 
 
 
Figure (3) Routes of mechanism of resistance in Enterococcal species (21) 
 
Figure (3) demonstrates different routes by which Enterococci can develop 
resistance towards several antibiotics. We know that Enterococci are intrinsically 
resistant to various drugs and can develop resistance to other antibiotics by 
genetic mutations and exogenous gene transfer. Table (1) summarizes the 
resistance mechanisms for some of major classes of antibiotics. 
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Antibiotic 
Origin of 
resistance 
Site of 
resistance  
Notes 
Strategy of 
resistance 
          
β-lactams 
Intrinsic Cell wall 
Low-affinity PBPs 
allow peptidoglycan 
synthesis in the 
presence of β-lactams 
Decreased 
affinity for 
PBPs 
Acquired Cell wall 
β-Lactamase. Low-
level constitutive 
production may be 
missed on routine 
laboratory screening 
Drug 
inactivation 
          
Glycopeptides 
Acquired 
or intrinsic 
Cell wall 
Intrinsic low-level 
resistance 
in Enterococcus 
gallinarium and 
Enterococcus 
casseliflavus 
Altered target 
Daptomycin Acquired 
Cell 
membrane 
Mutations in the genes 
alter membrane 
structure and 
composition leading to 
either repulsion or 
diversion of the 
antibiotic from the cell 
membrane target 
Altered target 
          
Aminoglycosides Intrinsic Ribosome 
Polar molecules have 
difficulty penetrating to 
cytoplasm 
Decreased 
drug uptake 
          
Linezolid Intrinsic Ribosome 
Mutations in genes 
coding for 23S rRNA 
and transferable rRNA 
methyltransferase (cfr) 
Target 
modification 
 
Table (1) Mechanism of resistance in Enterococcus species (22) 
 
 
 
10 
 
1.3.1. Resistance to β-lactams 
 Penicillin or ampicillin monotherapy was the treatment of choice taken into 
consideration for Enterococcus infections for more than half a century (23). 
Resistance against penicillin is developed through production of penicillin-binding 
protein (PBP), which plays an important role in cell-wall integrity. Production of 
PBP5 is the main cause for ampicillin resistance, due to a low affinity for 
penicillins (24). During the 1970s and 1980s, high-resistance to ampicillin was 
reported in the United States (25). Another form of ampicillin resistance 
documented for E. faecium and E. faecalis is mediated by β-lactamase enzyme 
(23). β-lactamase enzyme cleavages through the β-lactam ring of the antibiotic 
rendering it inactive (26). Resistance to cephalosporins is associated with 
decrease in binding affinity to PBPs present in Enterococcus cells, particularly 
PBP5 (27, 28). PBP5 is a class B penicillin-binding protein; it possesses only 
transpeptidase enzymatic activity and therefore needs glycosyltransferase to 
produce peptidoglycan (22). Studies state that class A PBPs (PBPF, PONA, 
PBPZ) are present in E. faecium and E. faecalis. PBPF and PONA penicillin-
binding proteins play a role in cephalosporin resistance. PBPZ alone is unable to 
synthesize peptidoglycan. It has been documented that deletion of these three 
genes resulted in a susceptible mutant. However, this mutant was still active but 
shows an altered rate of growth (27, 28). Deletion of class A PBPs showed a 
decrease in penicillin and cephalosporin resistance (22). 
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1.3.2. Resistance to aminoglycosides 
 Resistance observed in the case of aminoglycosides is described as low-
level resistance and high-level resistance.  Low resistance causes low uptake of 
highly polar drug molecules (29). Such low to moderate level of resistance can 
be corrected by combination therapy with active agents like penicillins or 
vancomycin (30). However, this combination therapy does not work well with all 
the available aminoglycosides due to high-level acquired resistance (31, 32). 
High- level resistance is caused by ribosomal mutations that change S12 
ribosomal protein leading to altered target binding (33). 
 
1.3.3. Resistance to oxazolidinones 
 The resistance mechanism against oxazolidinones mainly occurs through 
mutations in the genes, which encode 23S ribosomal RNA ribosome-binding site, 
thus creating resistance to the drug of this class such as linezolid (34, 35). 
Another mechanism of resistance, which is actually more common, is plasmid 
mediated, gene cfr that encodes a methlytransferase that modifies position 
Å2503 of the 23S rRNA (36). 
 
1.3.4. Resistance to glycopeptides: 
 Glycopeptides like vancomycin bind to the terminal D-alanine-D-alanine 
(D-Ala-D-Ala) of the N-acetylmuramic acid (NAM) and N-acetylglucosamine 
(NAG) (37). This prevents cross-linking of the peptidoglycan chains and thus 
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inhibits cell wall synthesis (38). Resistance to glycopeptides results from 
alterations in peptidoglycan layer synthesis. This alteration results in reduction of 
the ability of the drug to bind to cell surface. 
Resistance to vancomycin results due to change in the terminal amino acids of 
the peptidoglycan precursor from D-alanine-D-alanine to D-alanine-D-lactate (D-
Ala-D-lac) or D-alanine-D-serine (D-Ala-D-Ser) (5). Low-level resistance is 
observed with D-Ala-D-Ser-ending precursors, resulting in decreased binding 
affinity about seven-fold and high-level resistance is observed with D-Ala-D-Lac-
ending precursors showing about 1000-fold decrease in binding affinity (22). 
 
1.3.5. Resistance to lipopeptides 
 Daptomycin, which is a potent lipopeptide drug, is used to treat VRE 
infections and shows bactericidal activity against Enterococci. Studies carried out 
on Daptomycin susceptible (DS) and Daptomycin non- susceptible (DNS) strains 
demonstrated that mutation in two genes, one being LiaF involved in cell-
stressing response to antibiotic (39) and the other being gdpD, which encodes a 
glycerol-phosphodiester phosphodiesterase, and cls encoding for 
cardiolipinsynthase; can cause resistance (40, 41). They play an important role in 
metabolism of phospholipids (40). Resistance occurs through altered cell 
membrane and cell wall, which then disturbs the interaction of lipopeptides like 
daptomycin with the bacteria, causing less depolarization of the cell membrane 
(41). 
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Over the last two decades, an increasing number of virulent strains resistant 
to vancomycin (vancomycin resistant enterococcus, VRE) have been reported, 
out of which about 80% are Enterococcus faecium and approximately 9% are 
Enterococcus faecalis (42). The presence of multi-drug resistance creates 
challenge for the treatment of Enterococcus infections. 
 
• Proposed mechanism of DAP resistance in enterococci 
Recently, Arias et al. proposed two ways in which daptomycin resistance 
takes place in Enterococcus (22). The first mechanism is that the drug is diverted 
from the division-septum, which is the actual site of action for daptomycin. This 
takes place due to the redistribution of cardiolipin micro-domains, which bind to 
daptomycin and divert it away from the division-septum. Such mechanism takes 
place in Enterococcus faecalis only.  
The second mechanism is observed in Enterococcus faecium. In this 
mechanism, positively charged daptomycin driven away from the cell membrane 
by positive electrostatic repulsion (22). This results mainly from changes in two 
genes, YycFG and cls; which cause changes in cell wall stress response (43-45). 
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Figure (4) Proposed mechanism of DAP resistance in Enterococcus (22) 
 
Daptomycin non-susceptibility is a major concern. Synergy of daptomycin with β-
lactams agents has been documented against Staphylococcus species (46-48). 
Several documented in vitro studies have been able to demonstrate synergistic 
activity against Enterococci with a combination of daptomycin and β-lactams (49, 
50). Combinations of daptomycin with β-lactams like ceftaroline (CPT), 
ceftriaxone (CRO), and ampicillin (AMP) demonstrated bactericidal results. In-
fact ceftaroline was observed to restore daptomycin’s susceptibility against DAP-
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NS strain (49). Studies state that lowered cell surface charge and increased 
daptomycin binding boost daptomycin’s bactericidal activity (49-51). It has also 
been documented that DAP+CPT is effective against E. faecalis; while 
DAP+AMP showed enhanced efficacy against E. faecium and E. faecalis (50, 52, 
53). Based on these observations, it can be concluded that there is some 
mechanism of synergy between daptomycin and β-lactams. 
 
 
 
1.4. Proposed mechanism of synergy 
 Daptomycin’s bactericidal activity is enhanced in presence of β-lactams. 
There have been two proposed mechanisms for this synergy. When a bacterial 
cell is exposed to a β-lactam, the negative charge on its surface is increased. 
This change increasing the attraction of DAP molecules towards the cell causing 
more bactericidal activity (54). The process explained further is self-described but 
not yet verified. 
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Figure (5) Proposed mechanism of synergy I, (A.) DAP molecules getting 
attached to the cell, (B.) DAP molecules attaching to the cell after the cell has 
been exposed to β-lactam. 
 
  As shown in figure (5A), there is a bacterial cell and there are partial 
positive and negative charges. When this cell is exposed to daptomycin, the DAP 
molecules attach to the negative molecules on the cell wall. In figure (5B), the 
bacterial cell is initially treated with a β-lactam antibiotic and then exposed to 
daptomycin. Treating with β-lactam antibiotic increases the number of negative 
molecules on the cell wall, which further leads to a higher number of DAP 
molecules attaching to the cell surface. This results in more bactericidal activity.  
  β-lactam antibiotics force bacteria to activate the flipase enzyme. This 
enzyme flips the phospholipid bi-layer. This process results due to change of 
alanine group to lysine group. The actual mechanism of this process is still 
unknown and has not been fully elucidated.  
  The second and more plausible mechanism is that the action of β-lactam 
antibiotic and their target PBP alters the integrity of the cell wall allowing for more 
DAP molecules to bind to the cytoplasmic membrane. As shown in figure (6.), a 
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perfectly healthy cell wall gets damaged when exposed to β-lactam antibiotics 
leading to alteration in the cell wall integrity. When daptomycin is introduced, 
more number of DAP molecules penetrate through the loosened and damaged 
cell wall easily and get attached to the cell membrane as compared to normal 
healthy cell.  This causes increase in DAP’s bactericidal activity. 
 
 
Figure (6) Proposed mechanism of synergy II, (A.) Healthy cell wall and a cell 
membrane, (B.) Disruption of cell wall after exposure of β-lactam antibiotics, (C.) 
DAP molecules attacking the cell membrane. 
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1.5. Cathelicidin peptide LL-37 
 LL-37 is a cationic peptide, which is a part of the innate human system. It 
belongs to the family of polypeptides found in lysosomes of macrophages and 
polymorphonuclear leukocytes (PMNs). It is known to show a wide range of 
immunomodulatory activates and direct antimicrobial, antifungal and antiviral 
properties (55). The mechanism of action of LL-37 is similar to daptomycin (56). 
Till date, the actual mechanism behind their activity is not yet determined 
conclusively, however the leading hypothesis states that LL37 is membrane 
active and it breaks the integrity of the cell membrane of the bacteria (57). As 
mentioned earlier, β-lactam antibiotics like CPT, CRO, and AMP enhance 
daptomycin’s activity, LL-37 also has some effect on β-lactam activity. LL-37 
synergy with β-lactam can also potentially help in avoiding daptomycin 
resistance. 
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CHAPTER 2 
HYPOTHESIS AND SPECIFIC AIMS 
 
Multi-drug resistance is a crucial problem we are facing today. Currently 
available therapies are either limited by bacteriostatic activity or the adverse 
effects the therapy can cause. New alternate therapies to overcome this 
resistance while avoiding such adverse effects are necessary. One such 
approach that looks promising is combination therapy. The primary aim of our 
study was to test unique combinations of various β-lactam antibiotics with 
daptomycin against Enterococcus faecium and Enterococcus faecalis organisms 
to assess the potential of this mechanism of synergy and check if some β-
lactams demonstrate better synergy with daptomycin against Enterococci than 
others. Our study also evaluated the ability of β-lactam antibiotics to affect 
human cathelicidin peptide LL-37’s antimicrobial activity which could possibly be 
vital in indirectly avoiding daptomycin resistance.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. Materials 
3.1.1. Bacterial strains 
  Fifteen E. faecalis and twenty E. faecium strains were selected for 
susceptibility studies. All these strains were ampicillin and vancomycin non-
susceptible. Two clinical strains of E. faecalis and one clinical, isogenic strain 
pair of E. faecium were selected for the time-kill studies. E. faecalis strains 
R6981 and R7808 were daptomycin-susceptible strains having MIC value of 
2mg/L. These clinical strains were chosen due to their resistant nature towards 
all the β-lactams tested. An isogenic strain pair of E. faecium was selected out of 
which parent strain 8019 was daptomycin-susceptible having a MIC value of 
2mg/L and its mutant strain 5938, which is daptomycin non-susceptible having a 
MIC value of 32mg/L. As mentioned previously, the susceptibility break-point for 
daptomycin is defined as MIC > 4mg/L (58). 
 
3.1.2. Media 
   Media used to culture Enterococcus species was Brain-heart Infusion agar 
(BHI), which is one of the best media for Enterococcal growth (59). Muller-Hilton 
broth (MHB). This highly nutritious medium was used for susceptibility studies 
and time kill assays. MHB was supplemented with 50mg/L of calcium and 
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12.5mg/L of magnesium. As discussed earlier, DAP mechanism of action is 
calcium dependent, addition of calcium to the media was important. 
 
3.1.3.  Antimicrobials 
  Daptomycin was the primary drug used for all studies performed. 
Daptomycin (Cubicin) was purchased commercially from Cubist Pharmaceutical, 
Lexington, MA, USA. A wide-range of β-lactams were selected from broad and 
narrow spectrum antibiotics which included 1st, 2nd, 3rd, 4th generation 
cephalosporins, carbapenems and penicillins. Cefazolin, cefotaxime, ceftriaxone, 
cefepime, ampicillin and ertapenem were purchased commercially from Sigma 
Chemical Co., St Louis, MO, USA. Ceftaroline powder was obtained from Actavis 
(Formally Forest Laboratories Inc., San Francisco, CA, USA). LL-37, the cationic 
cathelicidin antimicrobial peptide was purchased from purchased from AnaSpec, 
Fremont, CA, USA. 
 
3.2. Methods 
During this study susceptibility studies were carried out with single antibiotic 
agents and in combination. Minimum inhibitory concentration values were 
determined for all Enterococcus strains. Time kill studies were carried out using 
daptomycin alone and in combination with β-lactams. Time kill study results help 
to interpret the bactericidal nature of the antibiotics tested and whether or not 
synergy by standard definitions was observed. Fluorescent daptomycin binding 
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studies were carried out to check if β-lactams had an effect on daptomycin 
binding. The LL-37 assay was performed to check if potential synergy, similar to 
daptomycin, with β-lactam antibiotics was observed indicating a potential 
synergistic action between β-lactams and the innate immune system. 
 
3.2.1. Susceptibility studies 
  Broth microdilution method was used to determine the minimum inhibition 
concentration (MIC) values at ~106 cfu/mL according to CLSI guidelines. All 
studies were carried out in duplicates to evaluate reproducibility.  The MIC value 
of daptomycin was determined with and without presence of β-lactam agents. In 
combination therapy, β-lactams were supplemented in the broth at their 
respective biological free peaks since Enterococci are intrinsically resistant to β-
lactams and it is not possible to attain 0.5x MIC in the clinical setting.  Evaluation 
of all samples was done after an incubation period of 24h at 35oC. Daptomycin 
MIC fold reduction from baseline was calculated as the standard broth 
microdilution MIC upon daptomycin MIC in presence of respective β-lactams 
agents. 
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3.2.2. Time-kill experiments 
 Time kill experiments were performed in MHB supplemented with 50 mg/L 
calcium and 12.5 mg/L magnesium as growth media. Each well received an initial 
bacterial inoculum of ~106 cfu/mL. Time kill experiments were performed in 
duplicate for all antibiotic regimens tested to ensure reproducibility. Daptomycin 
and the other antimicrobials were tested at 0.5 x MIC of each respective 
organism or biologic concentration, with biologic concentrations being used if 0.5 
x MIC was greater than what a standard dose would achieve in serum. We used 
0.5x MIC for daptomycin whether the organism was susceptible (breakpoint of 
< 4 mg/L) or not.  Since all of enterococci tested were resistant to the beta-lactam 
we simulated the human pharmacokinetic free Cmax (peak) concentration of the 
beta-lactam. All agents were tested alone and in combination with daptomycin 
against each strain. All agents were tested alone and in combination with 
daptomycin against each strain. 0.1 mL aliquots were obtained from each killing 
curve plate well at 0, 4, 8, and 24 hours. These samples were then serially 
diluted to the appropriate concentrations and plated using automatic spiral plating 
(WASP, DW Scientific, West Yorkshire, England). After 18-24 hours growth on 
BHI agar plates, bacterial colonies were counted using a laser colony counter 
(ProtoCOL, Synoptics Limited, Frederick, MD). Time kill curves were generated 
by plotting mean colony counts (log10 CFU/mL) versus time to compare 24-hour 
killing effects of monotherapy and combination antimicrobial exposure. Synergy 
was defined according to AAC guidelines 2012 as greater than or equal to 100-
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fold increase in bacterial killing compared to the most active constituent. 
Bactericidal activity was defined as greater than or equal to a 3 log10 cfu/mL 
reduction from baseline. Figure (6) demonstrates the definition if synergy and 
explains how to interpret a time-kill study graph. 
 
Figure (7) Definition of Synergy 
 
 
Numbers of colonies are represented on the Y-axis and hours of incubation are 
on the X-axis. The dotted line represented the growth curve when no drug was 
administered. Line below the dotted one represents the growth curve when drug 
A was administered. Drug b line indicates a static growth. However, when drug A 
and B were administered together the growth cure went down. If the difference 
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between the lowest active mono-drug and the combination is greater than 2 log 
units, then drug A and drug B are considered synergistic. 
 
3.2.3. Binding of Fluorescent daptomycin (BoDipy) 
 Fluorescent daptomycin binding studies were carried out on E. faecium 
strain 5938, as the strain demonstrated elevated resistance against daptomycin. 
Dr. George Sakoulas and his team at University of California, San Diego, carried 
out this study for us. Bacteria were grown to an OD600 of 0.6. They were grown 
for an additional 1h in the presence of β-lactam agents; 5mg/L of ceftaroline, 20 
mg/L of ceftriaxone, 10mg/L of imipenem; and in absence of a β-lactam agent. 
They were then incubated with 8mg/L of daptomycin-BoDipy (boron-
dipyrromethane) for 20min, followed by three times washing with medium to 
remove unincorporated label. Samples were then subjected to 1mg/L DAPI stain 
and then placed on 1% Agarose pad for imaging in an Applied Precision 
deconvolution fluorescence microscope. Images were shot for each sample 
using similar camera exposures, for quantification of daptomycin-BoDipy 
fluorescence. The average fluorescence intensity of individual pixels for the 
background was also measured and then subtracted from the cells to generate 
an accurate measurement of daptomycin-BoDipy binding (60). 
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3.2.4. LL-37 Assay 
 All strains were grown to a stationary phase (16 to 20 h) in lysogeny broth 
(LB) in either the presence or absence of antimicrobials ampicillin, ertapenem 
and ceftaroline; pelleted, washed with PBS, and exposed at an inoculum of 105 
CFU/ml to 4-128 µM LL-37 in RPMI-5% LB. The percentage of surviving bacteria 
(+/-SD) after 2h of incubation at 35°C was calculated by plating on BHI agar 
plates (59). 
 
3.2.5. Statistical analysis 
  Changes in CFU/mL for the killing curves were compared by one-way 
analysis of variance (ANOVA). A p-value of <0.05 was considered significant. All 
statistical analyses were performed using SPSS Statistical Software (Release 21, 
SPSS, Inc., Chicago, IL). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
4.1. Results 
4.1.1. Susceptibility studies 
  All the Enterococcus strains (15 strains of E. faecalis and 20 strains of E. 
faecium) were resistant to vancomycin and ampicillin. MIC values recorded 
against β-lactams demonstrated absolute resistance against the agents tested. 
The daptomycin MIC values recorded for these strains ranged from 2 to 128 
mg/L. However, it was observed that in the presence of β-lactam agents like 
ceftaroline, ampicillin, ertapenem, cefotaxime, ceftriaxone, cefepime and 
cefazolin; the daptomycin MIC value was reduced. Table (2) describes the 
statistical analysis of reduction observed in the daptomycin MIC when given in 
combination with various β-lactam agents against the Enterococcus strains. 
Ceftaroline combination with daptomycin demonstrated greatest reduction (32-
fold decrease) in the daptomycin MIC value as compared to other β-lactams in E. 
faecium. Statistical analysis in table (2) demonstrates that the average reduction 
observed in case of E. faecium was 8.4 ± 8.3-fold. The range of reduction was 4 
to 32-fold and median of reduction was 6-fold. In a descending order, ampicillin, 
ertapenem, ceftriaxone, cefepime, cefazolin and cefotaxime demonstrated 
reduction in daptomycin MIC as well. 
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Daptomycin combination MIC reductions against                                 
15 E. faecalis and 20 E. faecium strains 
 
Daptomycin MIC (fold reduction from baseline) 
mean SD median range 
   E. faecalis 
 
DAP+CPT 19.07 17.58 8 2~64 
 
DAP+FEP 12.00 18.98 2 1~64 
 
DAP+AMP 5.00 2.38 4 4~32 
 
DAP+ERT 4.27 3.37 4 2~16 
 
DAP+CRO 7.73 15.76 4 1~64 
 
DAP+CTX 1.80 1.01 2 1~4 
 
DAP+CFZ 3.33 0.98 4 2~4 
E. faecium 
 
DAP+CPT 8.40 8.30 6 4~32 
DAP+FEP 3.20 2.04 3 1~8 
DAP+AMP 6.00 2.31 6 4~8 
DAP+ERT 4.00 2.25 4 2~8 
DAP+CRO 3.30 2.18 2 2~8 
DAP+CTX 2.70 2.45 2 1~8 
DAP+CFZ 2.80 2.40 2 1~8 
  
CPT, ceftaroline; FEP, cefepime; AMP, ampicillin; ERT, 
ertapenem; CRO, ceftriaxone; CTX, cefotaxime; CFZ, cefazolin. 
 
Table (2) Statistical analysis of reduction in DAP MIC (61) 
 
 
Ceftaroline demonstrated the greatest DAP MIC reduction for E. faecalis 
as well. The greatest DAP reduction in MIC observed was 8-fold, average 
reduction recorded was 19.1 ± 17.6-fold with median 8 and range of 2 to 64-fold 
reduction as shown in table (2.). In a descending order after ceftaroline, greatest 
reduction in DAP MIC was demonstrated by ertapenem, ampicillin, cefepime, 
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ceftriaxone, cefazolin and cefotaxime. Figure (7) and figure (8) show graphical 
illustration of DAP MIC reduction in E. faecium strains (8019 and 5938), and in E. 
faecium strains (R6981 and R7808) respectively that were used for time-kill 
studies. 
 
 
  
 
Figure (8) Daptomycin MIC values against E. faecium strains 8019 and 5938, in 
the presence of several β-lactam agents. CPT, ceftaroline; ERT, ertapenem; 
AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; CFZ, 
cefazolin; CTX, ceftriaxone; No Combo, DAP MIC values without the presence of 
β-lactam agents(61). 
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Figure (9) Daptomycin MIC values against E. faecalis strains R6981 and R7808, 
in the presence of several β-lactam agents. CPT, ceftaroline; ERT, ertapenem; 
AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; CFZ, 
cefazolin; CTX, cefotaxime; No Combo, DAP MIC values without the presence of 
β-lactam agents(61). 
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4.1.2. Time-kill studies 
 
In figure (9-12), dotted line represents treatment with single drug and solid 
lines represent combination drug treatment.  
 
(A.) 
 
(B.) 
 
Figure (10) Twenty-four hour time-kill curves against strain 8019, (A.) Kill curves 
with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with DAP, (B.) 
kill curves with CTX, CFZ alone and in combination with DAP. 
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(A.) 
 
(B.) 
 
Figure (11) Twenty-four hour time-kill curves against strain 5938, (A.) Kill curves 
with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with DAP, (B.) 
kill curves with CTX, CFZ alone and in combination with DAP. 
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(A.) 
 
(B.) 
 
 
Figure (12) Twenty-four hour time-kill curves against strain R6981, (A.) Kill 
curves with DAP, AMP, CRO, CPT, FEP, ERT alone and in combination with 
DAP, (B.) kill curves with CTX, CFZ alone and in combination with DAP. 
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(A.) 
 
(B.) 
 
 
Figure (13) Twenty-four hour time-kill curves against strain R7808, (A.) Kill 
curves with DAP, AMP, CTX, CRO, CPT, FEP, ERT alone and in combination 
with DAP, (B.) kill curves with CFZ alone and in combination with DAP. 
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In the above figures (9-12); DAP, daptomycin; CPT, ceftaroline; ERT, 
ertapenem; AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; 
CFZ, cefazolin; CTX, cefotaxime; GC, drug-free growth control. 
  For strains 8019, 5938 and R6981, ceftaroline, ertapenem, ampicillin, 
ceftriaxone and cefepime demonstrated synergy with daptomycin as shown in 
figure (9a, 10a and 11a). However, cefazolin and cefotaxime were not synergistic 
(Figure 9b, 10b and 11b). Against strain R7808, except cefazolin all other β-
lactam agents demonstrated synergy with daptomycin (Figure 12a and 12b). The 
highest synergistic activity recorded was daptomycin with ertapenem against E. 
faecium strain 5938 (P <0.05). Except for this combination all other combinations 
demonstrated similar synergistic activity. However, bactericidal activity was not 
achieved with the combinations tested against the enterococcal isolates. 
 
4.1.3. Fluorescent daptomycin binding studies 
 The BoDipy daptomycin binding study was carried out on E. faecium 
(5938) strain. Strain samples were pretreated with sub-inhibitory concentrations 
of β-lactam agents like ceftaroline, imipenem and ceftriaxone and without any 
exposure of β-lactam. Images were captured after treating these samples with 
daptomycin. Fluorescent daptomycin was visualized in greenish-yellow color as 
shown in figure (13). Quantification results (Figure 14) demonstrated that 
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greatest binding of daptomycin was observed in the sample pretreated with 
ceftaroline as compared to any other sample (P<0.001). Ceftriaxone and 
imipenem show similar daptomycin binding as compared with no pretreatment.  
 
Figure (14) Fluorescent daptomycin (greenish-yellow colored) binding at 8mg/L 
to E. faecium strain 5938 cells (blue colored), (a) no pretreatment with β-lactam, 
(b) pretreated with 5mg/L of ceftaroline for 20mins, (c) pretreated with 10mg/L of 
imipenem for 20mins and (d) pretreated with 20mg/L of ceftriaxone for 
20mins(61). 
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Figure (15) Average intensity of fluorescently labeled daptomycin (BoDipy) 
against E. faecium strain 5938 after pretreatment with several β-lactam agents. 
CPT, ceftaroline; CRO, ceftriaxone; IPM, imipenem. Error bars indicate standard 
deviation(61). 
 
 
 
 
4.1.4. LL-37 assay 
LL-37 demonstrates a bactericidal mechanism of action that is similar to 
daptomycin. As per the results of the earlier studies, we demonstrated that β-
lactam antibiotics show synergy with daptomycin against Enterococcus species. 
This study was designed to determine if β-lactam antibiotics also demonstrate 
similar synergy with LL-37. 
One E. faecalis and two E. faecium strains were chosen for this assay 
study. β-lactams chosen for the study were ampicillin, ertapenem and ceftaroline 
38 
 
and all strains were exposed to subinhibitory concentrations of these β-lactams. 
Strains were grown in Lysogeny medium containing LL-37 in the presence and 
absence of β-lactam antibiotics. 
 
Figure (16) Percentage survival of Enterococcus species with 128 µM LL-37 in 
the presence and absence of free peak concentrations of β-lactam antibiotics 
AMP (70mg/L), ERT (15.5mg/L) and CPT (17mg/L). (A.) Strain 6981 (E. faecalis) 
(B.) Strain 6370 and (C.) Strain 8019 (E. faecium). Error bars indicate SD(59). 
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LL-37 microbicidal assay results are displayed graphically in figure (15). 
All the β-lactam antibiotics tested significantly (P <0.001) enhanced killing by LL-
37. Overall, LL-37 demonstrated maximum microbicidal activity when the strains 
were grown in the presence of ceftaroline. Against strain 6981, killing was 
significantly (P <0.001) enhanced when strain was exposed to CPT and ERT, 
while exposure to AMP yielded similar results as compared to no exposure (P 
<0.001) (Figure 15A). Highest killing against E. faecium strains 6370 was 
observed when strain was exposed to CPT and ERT as compared to AMP (P 
<0.001) (Figure 15B). Against E. faecium strain 8019, all three β-lactam 
antibiotics tested showed increased amount of killing by LL-37 as compared to 
no exposure (P <0.001) (Figure 15C). 
 
4.2. Discussion 
 Previous literature has demonstrated that β-lactam antibiotics may act 
synergistically with daptomycin. Most of these documented synergy studies were 
performed against Staphylococcus species but there is very little information of 
such synergistic activity against Enterococcus species. Therefore, the primary 
goal of this study was to explore this phenomenon in Enterococci. This study is 
one of the largest comparisons of multiple β-lactam antibiotic synergy with 
daptomycin against Enterococcus species. Our study demonstrated that β-lactam 
antibiotics like ceftaroline, ertapenem, ampicillin, cefepime and ceftriaxone lower 
the daptomycin MIC values. These agents also demonstrate synergistic activity 
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with daptomycin in time-kill assays against Enterococcus species. However, this 
phenomenon does not appear to be true for all β-lactam antibiotics as cefazolin 
and cefotaxime demonstrated little to no ability to enhance daptomycin’s 
bactericidal activity in time-kill assay. This inability of cefazolin and cefotaxime is 
most likely related to differences in the PBP profiles of these agents. Despite the 
enterococci being resistant to the beta-lactams, our assumption is that the beta-
lactam even at non-inhibitory or non-lethal concentrations still has some impact 
on the cell wall integrity thereby leading to increased daptomycin penetration 
through the cell wall and enhanced daptomycin binding at the cytoplasmic 
membrane. The difference in the greater synergy activity for ceftaroline, 
ampicillin and ertapenem may be related to their unique ability to bind multiple 
PBPs. 
 Every β-lactam antibiotics target specific PBPs to exhibit their respective 
inhibitory activity. Resistance to β-lactam antibiotics in enterococci is primarily a 
result of mutations leading to altered PBP profiles and hence loss of PBP binding 
affinity (62). It has been observed that β-lactam resistant enterococci have 
abundant PBP5. PBP5 has low affinity for binding of β-lactam antibiotics and 
hence it allows the organism to survive in the presence of a β-lactam agent (63). 
However, studies demonstrated that ceftaroline has binding affinity to PBP5 and 
therefore demonstrate some activity against resistant Enterococci. One such 
study performed by Henry X and group demonstrated the enhanced binding 
affinity to PBP5 as compared to other β-lactam agents, which explains why 
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ceftaroline demonstrated the greatest synergistic activity with daptomycin against 
Enterococci species (62). Some studies have demonstrated that ceftaroline 
binding affinity to PBPs 1-4, suggesting that saturations of several PBPs lead to 
increase antimicrobial activity. It has been observed in the previous findings that 
the saturation of PBPs 1-5 with combination of β-lactam agents increases 
antimicrobial activity against E. faecalis (62).  Recent clinical data suggest that 
combination of ampicillin with ceftriaxone can be effective for enterococcal 
infections, which also backs this assumption (64-66). Our study also suggested 
that the saturation of PBPs by ceftaroline and to a lesser extent by other β-lactam 
agents like ampicillin, ertapenem, ceftriaxone and cefepime, might play an 
important role in synergistic activity with daptomycin. Whereas, we presume that 
cefotaxime and cefazolin demonstrate more variable binding affinity to PBPs and 
no binding to PBP5 and hence fail to demonstrate synergy and enhance 
daptomycin’s activity. Similar explanation holds true for enhancement of LL-37’s 
activity when the strain is pretreated with β-lactam agents. 
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β-lactam 
antibiotic 
PBP selectivity 
    
CPT PBP1-4 & PBP5 
AMP 
Varies with different 
organisms 
CFZ 
FEP 
CRO PBP2 
CTX PBP2 
FOX PBP4 
ERT PBP? 
    
 
 
Table (3) PBP profile for β-lactam antibiotic (67). 
 
In addition to the above explanation, there is another possibility by which this 
synergistic activity can be explained. Ampicillin restores daptomycin activity in 
DAP-NS E. faecium having LiaFSR mutation, a system that is involved in the 
regulation of the cell stress response (68). Strain 8019 has been sequenced and 
has a known LiaFSR mutation. These mutations are often found in E. faecium 
species having MIC values of 2-4mg/L (69). There is a possibility that these 
isolates may harbor LiaFSR mutation, and it is possible that several β-lactam 
agents may restore daptomycin’s activity against such DAP-NS organisms. 
Studies to confer specific mutations that are related with β-lactam synergy need 
more investigation into LiaFSR mutations; mutations present in cardiolipin 
synthase (cls) gene, which confers changes in membrane orientation of 
43 
 
cardiolipins in the E. faecalis cell membrane, and yyCFGHIJ, a regulator of cell 
wall homeostasis (68, 70). A study carried out by Cesar Arias and his group at 
Houston demonstrated synergy between ampicillin and daptomycin on strains of 
E. faecium with LiaFSR mutations (69). 
 Resistance to daptomycin therapy among E. faecalis has been 
demonstrated by diverting the daptomycin molecules away from the division 
septum, which is the primary site of action (70). In addition, resistance in E. 
faecium is demonstrated by lack of daptomycin binding (49, 50). Our study 
demonstrated that presence of subinhibitory concentration ceftaroline increased 
daptomycin activity against a DAP-NS strain 5938. Among all the β-lactam 
antibiotics tested, ceftaroline was superior to all others against this strain, which 
may be explained by the enhanced PBP binding profile of ceftaroline. 
 Daptomycin in combination with β-lactam antibiotics demonstrated 
impressive results in broth microdilution MIC testing. There is clinical evidence of 
ceftaroline demonstrating synergistic activity with daptomycin against 
enterococcal infections; ampicillin is also frequently administered in combination 
therapy to treat such infections (52). Ertapenem is a broad spectrum Gram-
negative β-lactam antibiotic that shows potential in a setting of a prolonged 
antibiotic course to treat acute infections, as its simple one daily dosing regimen 
allows for uncomplicated outpatient therapy as compared to other more 
frequently administered parenteral β-lactam antibiotics (71). 
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 β-lactam antibiotics have also demonstrated enhancement of LL-37’s 
antimicrobial activity. The highest LL-37’s activity was achieved when strain was 
pretreated with ceftaroline as compared to other β-lactam agents. This further 
substantiates the ability of β-lactam antibiotics to improve antimicrobial activity 
including enhancing components of the innate immune system. 
 Further studies are warranted on a variety of different enterococcal 
strains to confirm the reproducibility of these results and the conclusion that our 
study suggests.  
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CHAPTER 5 
 
 
CONCLUSION 
  
 
  With the increasing number of vancomycin-resistant and ampicillin-
resistant Enterococci species, therapeutic alternative therapies to combat such 
infections are essential. Daptomycin is a bactericidal antibiotic and is used to 
treat VRE infections. However, daptomycin non-susceptibility is also a concern. 
Our study demonstrated the ability of β-lactam antibiotics to provide synergistic 
activity with daptomycin against such infections. In addition, this study also 
validates the ability of β-lactams to restore daptomycin’s activity in some 
enterococcal strains demonstrating non-susceptibility.  Also, our study suggests 
that if high-dose daptomycin were administered in combination with β-lactam 
antibiotics at an early stage, the therapy would demonstrate effective enhanced 
bactericidal activity and potentially avoid the development of daptomycin 
resistance. Our results suggest that use of β-lactam antibiotics with LL-37 
increases antibacterial activity of the cationic peptide LL-37 thus modulating the 
immune system. The finding suggests that the use of early β-lactam therapy may 
reduce the likelihood that DAP resistance may develop.  Future studies should 
explore whether the use of DAP in combination with β-lactams could also be 
DAP dosage sparing reducing the need for high-dose DAP regimens for the 
treatment of enterococcal infections. Our data would also suggest that not all 
enterococci may be susceptible to daptomycin plus a beta-lactam.  Based on 
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enterococcal PBP profiling or detection of specific mutations such as the 
presence of liaSFR mutations, it may be possible in the future to individualize 
patient therapy with technology. 
  
47 
 
REFERENCES 
 
1. Murray BE. 1990. The life and times of the Enterococcus. Clinical 
microbiology reviews 3:46-65. 
2. Gilmore MS. 2002. The enterococci : pathogenesis, molecular biology, 
and antibiotic resistance. ASM Press, Washington, D.C. 
3. Sydnor ER, Perl TM. 2011. Hospital epidemiology and infection control in 
acute-care settings. Clinical microbiology reviews 24:141-173. 
4. de Perio MA, Yarnold PR, Warren J, Noskin GA. 2006. Risk factors and 
outcomes associated with non-Enterococcus faecalis, non-Enterococcus 
faecium enterococcal bacteremia. Infection control and hospital 
epidemiology : the official journal of the Society of Hospital 
Epidemiologists of America 27:28-33. 
5. Courvalin P. 2006. Vancomycin resistance in gram-positive cocci. Clinical 
infectious diseases : an official publication of the Infectious Diseases 
Society of America 42 Suppl 1:S25-34. 
6. Sood S, Malhotra M, Das BK, Kapil A. 2008. Enterococcal infections & 
antimicrobial resistance. The Indian journal of medical research 128:111-
121. 
7. Fisher K, Phillips C. 2009. The ecology, epidemiology and virulence of 
Enterococcus. Microbiology 155:1749-1757. 
48 
 
8. Fisher JF, Meroueh SO, Mobashery S. 2005. Bacterial resistance to 
beta-lactam antibiotics: compelling opportunism, compelling opportunity. 
Chemical reviews 105:395-424. 
9. Mainardi JL, Morel V, Fourgeaud M, Cremniter J, Blanot D, Legrand 
R, Frehel C, Arthur M, Van Heijenoort J, Gutmann L. 2002. Balance 
between two transpeptidation mechanisms determines the expression of 
beta-lactam resistance in Enterococcus faecium. The Journal of biological 
chemistry 277:35801-35807. 
10. Antunes NT, Frase H, Toth M, Mobashery S, Vakulenko SB. 2011. 
Resistance to the third-generation cephalosporin ceftazidime by a 
deacylation-deficient mutant of the TEM beta-lactamase by the uncommon 
covalent-trapping mechanism. Biochemistry 50:6387-6395. 
11. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin 
nonsusceptible enterococci: an emerging challenge for clinicians. Clinical 
infectious diseases : an official publication of the Infectious Diseases 
Society of America 52:228-234. 
12. Thauvin C, Eliopoulos GM, Willey S, Wennersten C, Moellering RC, 
Jr. 1987. Continuous-infusion ampicillin therapy of enterococcal 
endocarditis in rats. Antimicrobial agents and chemotherapy 31:139-143. 
13. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr., Bolger AF, 
Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, 
Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, 
49 
 
Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on 
Rheumatic Fever E, Kawasaki D, Council on Cardiovascular Disease 
in the Y, Councils on Clinical Cardiology S, Cardiovascular S, 
Anesthesia, American Heart A, Infectious Diseases Society of A. 
2005. Infective endocarditis: diagnosis, antimicrobial therapy, and 
management of complications: a statement for healthcare professionals 
from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki 
Disease, Council on Cardiovascular Disease in the Young, and the 
Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and 
Anesthesia, American Heart Association: endorsed by the Infectious 
Diseases Society of America. Circulation 111:e394-434. 
14. Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, 
Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. 
2013. Multicenter study of high-dose daptomycin for treatment of 
enterococcal infections. Antimicrobial agents and chemotherapy 57:4190-
4196. 
15. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin 
regimens against clinical strains of glycopeptide intermediate-resistant 
Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and 
methicillin-resistant Staphylococcus aureus isolates in an in vitro 
pharmacodynamic model with simulated endocardial vegetations. 
Antimicrobial agents and chemotherapy 45:454-459. 
50 
 
16. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. 2012. Evaluation 
of standard- and high-dose daptomycin versus linezolid against 
vancomycin-resistant Enterococcus isolates in an in vitro 
pharmacokinetic/pharmacodynamic model with simulated endocardial 
vegetations. Antimicrobial agents and chemotherapy 56:3174-3180. 
17. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, 
Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. 2013. A multicentre 
evaluation of the effectiveness and safety of high-dose daptomycin for the 
treatment of infective endocarditis. The Journal of antimicrobial 
chemotherapy 68:2921-2926. 
18. Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, 
Rybak MJ. 2015. Ceftobiprole and ampicillin increase daptomycin 
susceptibility of daptomycin-susceptible and -resistant VRE. The Journal 
of antimicrobial chemotherapy 70:489-493. 
19. Baltz RH. 2009. Daptomycin: mechanisms of action and resistance, and 
biosynthetic engineering. Current opinion in chemical biology 13:144-151. 
20. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated 
reorganization of membrane architecture causes mislocalization of 
essential cell division proteins. Journal of bacteriology 194:4494-4504. 
21. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond 
vancomycin resistance. Nature reviews. Microbiology 10:266-278. 
51 
 
22. Miller WR, Munita JM, Arias CA. 2014. Mechanisms of antibiotic 
resistance in enterococci. Expert review of anti-infective therapy 12:1221-
1236. 
23. Murray BE. 1992. Beta-lactamase-producing enterococci. Antimicrobial 
agents and chemotherapy 36:2355-2359. 
24. Fontana R, Ligozzi M, Pittaluga F, Satta G. 1996. Intrinsic penicillin 
resistance in enterococci. Microbial drug resistance 2:209-213. 
25. Galloway-Pena JR, Nallapareddy SR, Arias CA, Eliopoulos GM, 
Murray BE. 2009. Analysis of clonality and antibiotic resistance among 
early clinical isolates of Enterococcus faecium in the United States. The 
Journal of infectious diseases 200:1566-1573. 
26. Coudron PE, Markowitz SM, Wong ES. 1992. Isolation of a beta-
lactamase-producing, aminoglycoside-resistant strain of Enterococcus 
faecium. Antimicrobial agents and chemotherapy 36:1125-1126. 
27. Arbeloa A, Segal H, Hugonnet JE, Josseaume N, Dubost L, Brouard 
JP, Gutmann L, Mengin-Lecreulx D, Arthur M. 2004. Role of class A 
penicillin-binding proteins in PBP5-mediated beta-lactam resistance in 
Enterococcus faecalis. Journal of bacteriology 186:1221-1228. 
28. Rice LB, Carias LL, Rudin S, Hutton R, Marshall S, Hassan M, 
Josseaume N, Dubost L, Marie A, Arthur M. 2009. Role of class A 
penicillin-binding proteins in the expression of beta-lactam resistance in 
Enterococcus faecium. Journal of bacteriology 191:3649-3656. 
52 
 
29. Chow JW. 2000. Aminoglycoside resistance in enterococci. Clinical 
infectious diseases : an official publication of the Infectious Diseases 
Society of America 31:586-589. 
30. Moellering RC, Jr., Weinberg AN. 1971. Studies on antibiotic syngerism 
against enterococci. II. Effect of various antibiotics on the uptake of 14 C-
labeled streptomycin by enterococci. The Journal of clinical investigation 
50:2580-2584. 
31. Hollingshead S, Vapnek D. 1985. Nucleotide sequence analysis of a 
gene encoding a streptomycin/spectinomycin adenylyltransferase. 
Plasmid 13:17-30. 
32. Krogstad DJ, Korfhagen TR, Moellering RC, Jr., Wennersten C, 
Swartz MN. 1978. Aminoglycoside-inactivating enzymes in clinical 
isolates of Streptococcus faecalis. An explanation for resistance to 
antibiotic synergism. The Journal of clinical investigation 62:480-486. 
33. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. 
Aminoglycosides: activity and resistance. Antimicrobial agents and 
chemotherapy 43:727-737. 
34. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini 
P. 2008. The oxazolidinone antibiotics perturb the ribosomal peptidyl-
transferase center and effect tRNA positioning. Proceedings of the 
National Academy of Sciences of the United States of America 
105:13339-13344. 
53 
 
35. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco 
LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS. 2007. The site 
of action of oxazolidinone antibiotics in living bacteria and in human 
mitochondria. Molecular cell 26:393-402. 
36. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin 
AS. 2007. Acquisition of a natural resistance gene renders a clinical strain 
of methicillin-resistant Staphylococcus aureus resistant to the synthetic 
antibiotic linezolid. Molecular microbiology 64:1506-1514. 
37. Werner G, Strommenger B, Witte W. 2008. Acquired vancomycin 
resistance in clinically relevant pathogens. Future microbiology 3:547-562. 
38. Arthur M, Courvalin P. 1993. Genetics and mechanisms of glycopeptide 
resistance in enterococci. Antimicrobial agents and chemotherapy 
37:1563-1571. 
39. Jordan S, Junker A, Helmann JD, Mascher T. 2006. Regulation of 
LiaRS-dependent gene expression in bacillus subtilis: identification of 
inhibitor proteins, regulator binding sites, and target genes of a conserved 
cell envelope stress-sensing two-component system. Journal of 
bacteriology 188:5153-5166. 
40. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, 
Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren 
E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock 
54 
 
GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. 
The New England journal of medicine 365:892-900. 
41. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011. Genetic 
basis for daptomycin resistance in enterococci. Antimicrobial agents and 
chemotherapy 55:3345-3356. 
42. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, 
Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network 
T, Participating NF. 2013. Antimicrobial-resistant pathogens associated 
with healthcare-associated infections: summary of data reported to the 
National Healthcare Safety Network at the Centers for Disease Control 
and Prevention, 2009-2010. Infection control and hospital epidemiology : 
the official journal of the Society of Hospital Epidemiologists of America 
34:1-14. 
43. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, 
Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock 
GM, Arias CA. 2013. Whole-genome analysis of a daptomycin-
susceptible enterococcus faecium strain and its daptomycin-resistant 
variant arising during therapy. Antimicrobial agents and chemotherapy 
57:261-268. 
44. Dubrac S, Bisicchia P, Devine KM, Msadek T. 2008. A matter of life and 
death: cell wall homeostasis and the WalKR (YycGF) essential signal 
transduction pathway. Molecular microbiology 70:1307-1322. 
55 
 
45. Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E, Dowhan 
W, Guan Z, Arias CA. 2012. Daptomycin resistance in enterococci is 
associated with distinct alterations of cell membrane phospholipid content. 
PloS one 7:e43958. 
46. Barber KE, Werth BJ, Rybak MJ. 2015. The combination of ceftaroline 
plus daptomycin allows for therapeutic de-escalation and daptomycin 
sparing against MRSA. The Journal of antimicrobial chemotherapy 
70:505-509. 
47. Werth BJ, Barber KE, Ireland CE, Rybak MJ. 2014. Evaluation of 
ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin 
against daptomycin-nonsusceptible methicillin-resistant Staphylococcus 
aureus in an in vitro pharmacokinetic/pharmacodynamic model of 
simulated endocardial vegetations. Antimicrobial agents and 
chemotherapy 58:3177-3181. 
48. Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ. 
2015. Evaluation of Ceftaroline Alone and in Combination against Biofilm-
Producing Methicillin-Resistant Staphylococcus aureus with Reduced 
Susceptibility to Daptomycin and Vancomycin in an In Vitro 
Pharmacokinetic/Pharmacodynamic Model. Antimicrobial agents and 
chemotherapy 59:4497-4503. 
49. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, 
Nizet V. 2014. Ceftaroline restores daptomycin activity against 
56 
 
daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. 
Antimicrobial agents and chemotherapy 58:1494-1500. 
50. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, 
Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin- 
and cationic host defense peptide-mediated killing of ampicillin- and 
vancomycin-resistant Enterococcus faecium. Antimicrobial agents and 
chemotherapy 56:838-844. 
51. Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. 2014. 
Evaluation of the novel combination of daptomycin plus ceftriaxone 
against vancomycin-resistant enterococci in an in vitro 
pharmacokinetic/pharmacodynamic simulated endocardial vegetation 
model. The Journal of antimicrobial chemotherapy 69:2148-2154. 
52. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, 
Haddad F. 2013. Treatment of high-level gentamicin-resistant 
Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. 
Antimicrobial agents and chemotherapy 57:4042-4045. 
53. Sierra-Hoffman M, Iznaola O, Goodwin M, Mohr J. 2012. Combination 
therapy with ampicillin and daptomycin for treatment of Enterococcus 
faecalis endocarditis. Antimicrobial agents and chemotherapy 56:6064. 
54. Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. 2013. Reduced 
glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and 
the "seesaw effect": Taking advantage of the back door left open? Drug 
57 
 
resistance updates : reviews and commentaries in antimicrobial and 
anticancer chemotherapy 16:73-79. 
55. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-
37, a cathelin-associated antimicrobial peptide of human neutrophils. 
Antimicrobial agents and chemotherapy 42:2206-2214. 
56. Mensa B, Howell GL, Scott R, DeGrado WF. 2014. Comparative 
mechanistic studies of brilacidin, daptomycin, and the antimicrobial 
peptide LL16. Antimicrobial agents and chemotherapy 58:5136-5145. 
57. Shai Y. 2002. Mode of action of membrane active antimicrobial peptides. 
Biopolymers 66:236-248. 
58. Humphries RM, Kelesidis T, Tewhey R, Rose WE, Schork N, Nizet V, 
Sakoulas G. 2012. Genotypic and phenotypic evaluation of the evolution 
of high-level daptomycin nonsusceptibility in vancomycin-resistant 
Enterococcus faecium. Antimicrobial agents and chemotherapy 56:6051-
6053. 
59. Smith JR, Barber KE, Raut A, Rybak MJ. 2015. beta-Lactams enhance 
daptomycin activity against vancomycin-resistant Enterococcus faecalis 
and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic 
models. Antimicrobial agents and chemotherapy 59:2842-2848. 
60. Pogliano J, Osborne N, Sharp MD, Abanes-De Mello A, Perez A, Sun 
YL, Pogliano K. 1999. A vital stain for studying membrane dynamics in 
58 
 
bacteria: a novel mechanism controlling septation during Bacillus subtilis 
sporulation. Molecular microbiology 31:1149-1159. 
61. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. 
2015. beta-Lactam combinations with daptomycin provide synergy against 
vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. 
The Journal of antimicrobial chemotherapy 70:1738-1743. 
62. Henry X, Verlaine O, Amoroso A, Coyette J, Frere JM, Joris B. 2013. 
Activity of ceftaroline against Enterococcus faecium PBP5. Antimicrobial 
agents and chemotherapy 57:6358-6360. 
63. Rice LB, Carias LL, Hutton-Thomas R, Sifaoui F, Gutmann L, Rudin 
SD. 2001. Penicillin-binding protein 5 and expression of ampicillin 
resistance in Enterococcus faecium. Antimicrobial agents and 
chemotherapy 45:1480-1486. 
64. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. 1995. Synergistic 
effect of amoxicillin and cefotaxime against Enterococcus faecalis. 
Antimicrobial agents and chemotherapy 39:1984-1987. 
65. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de 
Alarcon A, Ruiz J, Vilacosta I, Montejo M, Vallejo N, Lopez-Medrano 
F, Plata A, Lopez J, Hidalgo-Tenorio C, Galvez J, Saez C, Lomas JM, 
Falcone M, de la Torre J, Martinez-Lacasa X, Pahissa A. 2013. 
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for 
treating enterococcus faecalis infective endocarditis. Clinical infectious 
59 
 
diseases : an official publication of the Infectious Diseases Society of 
America 56:1261-1268. 
66. Liao CH, Huang YT, Tsai HY, Hsueh PR. 2014. In vitro synergy of 
ampicillin with gentamicin, ceftriaxone and ciprofloxacin against 
Enterococcus faecalis. International journal of antimicrobial agents 44:85-
86. 
67. Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. 2013. beta-Lactam 
antibiotics targeting PBP1 selectively enhance daptomycin activity against 
methicillin-resistant Staphylococcus aureus. Antimicrobial agents and 
chemotherapy 57:5005-5012. 
68. Diaz L, Tran TT, Munita JM, Miller WR, Rincon S, Carvajal LP, Wollam 
A, Reyes J, Panesso D, Rojas NL, Shamoo Y, Murray BE, Weinstock 
GM, Arias CA. 2014. Whole-genome analyses of Enterococcus faecium 
isolates with diverse daptomycin MICs. Antimicrobial agents and 
chemotherapy 58:4527-4534. 
69. Munita JM, Panesso D, Diaz L, Tran TT, Reyes J, Wanger A, Murray 
BE, Arias CA. 2012. Correlation between mutations in liaFSR of 
Enterococcus faecium and MIC of daptomycin: revisiting daptomycin 
breakpoints. Antimicrobial agents and chemotherapy 56:4354-4359. 
70. Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan Z, Munita 
JM, Reyes J, Diaz L, Weinstock GM, Murray BE, Shamoo Y, Dowhan 
W, Bayer AS, Arias CA. 2013. Daptomycin-resistant Enterococcus 
60 
 
faecalis diverts the antibiotic molecule from the division septum and 
remodels cell membrane phospholipids. mBio 4. 
71. Odenholt I. 2001. Ertapenem: a new carbapenem. Expert opinion on 
investigational drugs 10:1157-1166. 
 
  
61 
 
ABSTRACT 
 
EXPLORING DAPTOMYCIN COMBINATION WITH β-LACTAM SYNERGY 
AGAINST SUSCEPTIBLE AND NON-SUSCEPTIBLE ENTEROCOCCI 
SPECIES 
 
by 
ANIMESH RAUT 
August 2015 
Advisor: Dr. Michael J. Rybak 
Major: Pharmaceutical sciences 
Degree: Master of Science 
 
Objective: Enterococcus faecalis and Enterococcus faecium are generally 
resistant to daptomycin and β-lactam antibiotics. However, documented in vitro 
data suggests synergy between several β-lactam antibiotics and daptomycin 
against resistant organisms. Primary goal of the study was to check various 
combinations of β-lactam antibiotics with daptomycin (DAP) and assess the 
potential of synergy and conclude which could be the superior combination. 
Study also evaluated potential of β-lactam antibiotics to enhance activity of LL-
37, which is a cationic peptide demonstrating bacteriostatic activity similar to 
DAP.  
Methods: Fifteen E. faecalis and twenty E. faecium strains were evaluated DAP 
enhancement via combination MICs. DAP MICs were obtained by broth 
microdilution in the absence and presence of various β-lactam antibiotics. Time-
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kill studies were carried out on two E. faecalis (R6981 and R7808) and one 
isogenic DAP-susceptible/ DAP-non-susceptible E. faecium strain (8019/5938). 
DAP was tested at 0.5x MIC with β-lactam antibiotics at free peak 
concentrations. Fluorescent DAP (BoDipy) was used to evaluate DAP binding 
studies on an E. faecium strain (5938). Two E. faecium (R6370 and 8019) and 
one E. faecalis (R6981) strains were chosen for evaluating enhancement of 
killing by LL-37 in the presence and absence of β-lactam antibiotics. 
Results: Highest reduction in DAP MIC value was observed when given in 
combination with ceftaroline. Ceftaroline (CPT), ertapenem (ERT), ampicillin 
(AMP), cefepime (FEP) and ceftriaxone (CRO) demonstrated synergy with DAP 
in time-kill studies. However, DAP synergy was observed with cefazolin (CFZ) 
and cefotaxime (CTX) only in one strain (R7808). In DAP binding studies, 
ceftaroline enhanced the DAP binding most as compared to other β-lactam 
antibiotics tested (P <0.001). In LL-37 assay study, CPT, AMP and ERT 
enhanced LL-37’s killing against strain 8019. For strain R6981 and R6370, LL-37 
demonstrated better killing with CPT and ERT as compared to AMP (P <0.001).  
Conclusion: Results of out study conclude that the use of DAP in combination 
with β-lactam antibiotics to treat resistant Enterococcus infections is lucrative. 
Combination regimens as compared to DAP alone demonstrate better killing. 
Combination also enhanced LL-37’s activity, which could possibly be a way to 
avoid DAP resistance. Overall, our data supports the evidence that combination 
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therapy of daptomycin with β-lactams maybe be helpful in combating non-
susceptible Enterococcus strains. 
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